tbuckley/cabot-search huggingface dataset:
Abstract 5410: Aspirin attenuates tumor initiating cell growth and induces reprogramming factors of mesenchymal to epithelial transition in breast cancer cell
Authors: Gargi Maity, Archana De, Snigdha Banerjee, Amlan Das, Sandipto Sarkar, Sushanta K. Banerjee
Journal: Cancer Research (2015)

Abstract Acetyl Salicylic Acid (ASA) also known as aspirin, a classic, non-steroidal, anti-inflammatory drug (NSAIDs) is widely used to relieve minor aches and pains and to reduce fever. Epidemiological studies and other experimental studies suggest that ASA use reduces the risk of different cancers including breast cancer (BC) and may be used as a chemo-preventive agent against BC and other cancers. These studies have raised the tempting possibility that ASA could serve as a preventive medicine for BC. However, lack of in-depth knowledge of the mechanism of action of ASA reshapes the debate of risk and benefit of using ASA in prevention. Our studies, using in vitro and in vivo tumor xenograft model, show a strong beneficial effect of ASA in the prevention of breast carcinogenesis. We find ASA not only prevents breast tumor cell growth in vitro and tumor growth in nude mice xenograft model through the induction of apoptosis, it also significantly reduces the growth of tumor initiating cells (TICs)/ cancer stem cells (CSCs) and delayed the formation of a palpable tumor. Moreover, ASA regulates other pathophysiological events in breast carcinogenesis, such as reprogramming the mesenchymal to epithelial transition (MET) and delaying in vitro migration in BC cells. The tumor growth-inhibitory as well as reprogramming roles of ASA could be mediated through inhibition of TGF-β-signaling pathway, which is associated with growth, motility, invasion and metastasis in advanced breast cancers. Collectively, ASA has a therapeutic or preventive potential by attacking possible target such as TGF-β- SMAD4 signaling in breast carcinogenesis. [This work is funded by VA Merit Awarded Grant (SB and SKB)] Note: This abstract was not presented at the meeting. Citation Format: Gargi Maity, Archana De, Snigdha Banerjee, Amlan Das, Sandipto Sarkar, Sushanta K. Banerjee. Aspirin attenuates tumor initiating cell growth and induces reprogramming factors of mesenchymal to epithelial transition in breast cancer cell. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5410. doi:10.1158/1538-7445.AM2015-5410
Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list
Authors: Jagpreet Chhatwal, Sumeyye Samur, Brian Kues, Turgay Ayer, Mark S. Roberts, Fasiha Kanwal, Chin Hur, Drew Michael S. Donnell, Raymond T. Chung
Journal: Hepatology (2016)

The availability of oral direct‐acting antivirals has altered the hepatitis C virus (HCV) treatment paradigm for both pre–liver transplant (LT) and post‐LT patients. There is a perceived trade‐off between pre‐LT versus post‐LT treatment of HCV—treatment may improve liver function but potentially decrease the likelihood of a necessary LT. Our objective was to identify LT‐eligible patients with decompensated cirrhosis who would benefit (and not benefit) from pre‐LT treatment based on their Model for End‐Stage Liver Disease (MELD) scores. We simulated a virtual trial comparing long‐term outcomes of pre‐LT versus post‐LT HCV treatment with oral direct‐acting antivirals for patients with MELD scores between 10 and 40. We developed a Markov‐based microsimulation model, which simulated the life course of patients on the transplant waiting list and after LT. Simulation of LT integrated data from recent trials of oral direct‐acting antivirals (SOLAR 1 and 2), the United Network for Organ Sharing (UNOS), and other studies. The outcomes of the model included life expectancy, 1‐year and 5‐year patient survival, and mortality. Model‐predicted patient survival was validated with UNOS data. We found that, at the national level, treating HCV before LT increased life expectancy if MELD was ≤27 but could decrease life expectancy at higher MELD scores. Depending on the UNOS region, the threshold MELD score to treat HCV pre‐LT varied between 23 and 27 and was lower for UNOS regions 3, 10, and 11 and higher for regions 1, 2, 4, 5, 8, and 9. Sensitivity analysis showed that the thresholds were stable. Conclusion : Our findings suggest that the optimal MELD threshold below which decompensated cirrhosis patients should receive HCV treatment while awaiting LT is between 23 and 27, depending on the UNOS region. (H epatology 2017;65:777‐788)
NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability
Authors: Kamalakannan Palanichamy, Suman Kanji, Nicolaus Gordon, Krishnan Thirumoorthy, John R. Jacob, Kevin T. Litzenberg, Disha Patel, Arnab Chakravarti
Journal: Clinical Cancer Research (2016)

Purpose: To identify potential molecular hubs that regulate oncogenic kinases and target them to improve treatment outcomes for glioblastoma patients.Experimental Design: Data mining of The Cancer Genome Atlas datasets identified nicotinamide-N-methyl transferase (NNMT) as a prognostic marker for glioblastoma, an enzyme linked to the reorganization of the methylome. We tested our hypothesis that NNMT plays a crucial role by modulating protein methylation, leading to inactivation of tumor suppressors and activation of oncogenes. Further experiments were performed to understand the underlying biochemical mechanisms using glioblastoma patient samples, established, primary, and isogenic cells.Results: We demonstrate that NNMT outcompetes leucine carboxyl methyl transferase 1 (LCMT1) for methyl transfer from principal methyl donor SAM in biological systems. Inhibiting NNMT increased the availability of methyl groups for LCMT1 to methylate PP2A, resulting in the inhibition of oncogenic serine/threonine kinases (STK). Further, NNMT inhibition retained the radiosensitizer nicotinamide and enhanced radiation sensitivity. We have provided the biochemical rationale of how NNMT plays a vital role in inhibiting tumor suppressor PP2A while concomitantly activating STKs.Conclusions: We report the intricate novel mechanism in which NNMT inhibits tumor suppressor PP2A by reorganizing the methylome both at epigenome and proteome levels and concomitantly activating prosurvival STKs. In glioblastoma tumors with NNMT expression, activation of PP2A can be accomplished by FDA approved perphenazine (PPZ), which is currently used to treat mood disorders such as schizophrenia, bipolar disorder, etc. This study forms a foundation for further glioblastoma clinical trials using PPZ with standard of care treatment. Clin Cancer Res; 23(9); 2325-34. ©2016 AACR.
Functional and Genomic Architecture of Borrelia burgdorferi -Induced Cytokine Responses in Humans
Authors: Marije Oosting, Mariska Kerstholt, Rob ter Horst, Yang Li, Patrick Deelen, Sanne Smeekens, Martin Jaeger, Ekta Lachmandas, Hedwig Vrijmoeth, Mihaela Lupse, Mirela Flonta, Robert A. Cramer, Bart Jan Kullberg, Vinod Kumar, Ramnik Xavier, Cisca Wijmenga, Mihai G. Netea, Leo A.B. Joosten
Journal: Cell Host & Microbe (2016)
Response to Hepatitis B Vaccination Following Allogeneic Hematopoietic Cell Transplantation (HCT).
Authors: Trudy N. Small, Esperanza B. Papadopoulos, Farid Boulad, Hugo Castro-Malaspina, Ann Jakubowski, Nancy A. Kernan, Miguel Perales, Susan Prockop, James W. Young, Richard J. O’Reilly, Dana Jaffe
Journal: Blood (2005)
Use of Global Assays to Predict Bleeding Severity In Congenital Factor VII Deficiency.
Authors: Lindsey A. Greene, Neil A. Goldenberg, Chris Bombardier, Suchitra S. Acharya, Mindy L. Grunzke, Pedro J. Santiago-Borroro, Alejandro Cambara, Donna M. DiMichele
Journal: Blood (2010)
Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk
Authors: Yu Yin, Qingfu Zhang, Hong Zhang, Yiping He, Jiaoti Huang
Journal: Clinical Cancer Research (2016)

A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to stratify these patients into different risk groups. Clin Cancer Res; 23(1); 6-8. ©2016 AACRSee related article by Sinnott et al., p. 81.
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
Authors: Cheryl A. London, Heather L. Gardner, Sarah Rippy, Gerald Post, Krista La Perle, Linda Crew, Lori Lopresti-Morrow, Andrew J. Garton, Gerald McMahon, Theresa M. LaVallee, Richard Gedrich
Journal: Clinical Cancer Research (2016)

Purpose: KTN0158 is a novel anti-KIT antibody that potently inhibits wild-type and mutant KIT. This study evaluated the safety, biologic activity, and pharmacokinetic/pharmacodynamics profile of KTN0158 in dogs with spontaneous mast cell tumors (MCT) as a prelude to human clinical applications.Experimental Design: Cell proliferation, KIT phosphorylation, and mast cell degranulation were evaluated in vitro KTN0158 was administered to 4 research dogs to assess clinical effects and cutaneous mast cell numbers. Thirteen dogs with spontaneous MCT were enrolled into a prospective phase I dose-escalating open-label clinical study of KTN0158 evaluating 3 dose levels and 2 schedules and with weekly assessments for response and clinical toxicities.Results: KTN0158 was a potent inhibitor of human and dog KIT activation and blocked mast cell degranulation in vitro In dogs, KTN0158 was well tolerated and reduced cutaneous mast cell numbers in a dose-dependent manner. Clinical benefit of KTN0158 administration in dogs with MCT (n = 5 partial response; n = 7 stable disease) was observed regardless of KIT mutation status, and decreased KIT phosphorylation was demonstrated in tumor samples. Histopathology after study completion demonstrated an absence of neoplastic cells in the primary tumors and/or metastatic lymph nodes from 4 dogs. Reversible hematologic and biochemical adverse events were observed at doses of 10 and 30 mg/kg. The MTD was established as 10 mg/kg.Conclusions: KTN0158 inhibits KIT phosphorylation, demonstrates an acceptable safety profile in dogs, and provides objective responses in canine MCT patients with and without activating KIT mutations, supporting future clinical evaluation of KTN0158 in people. Clin Cancer Res; 23(10); 2565-74. ©2016 AACR.
To the Cloud! A Grassroots Proposal to Accelerate Brain Science Discovery
Authors: Joshua T. Vogelstein, Brett Mensh, Michael Häusser, Nelson Spruston, Alan C. Evans, Konrad Kording, Katrin Amunts, Christoph Ebell, Jeff Muller, Martin Telefont, Sean Hill, Sandhya P. Koushika, Corrado Calì, Pedro Antonio Valdés-Sosa, Peter B. Littlewood, Christof Koch, Stephan Saalfeld, Adam Kepecs, Hanchuan Peng, Yaroslav O. Halchenko, Gregory Kiar, Mu-Ming Poo, Jean-Baptiste Poline, Michael P. Milham, Alyssa Picchini Schaffer, Rafi Gidron, Hideyuki Okano, Vince D. Calhoun, Miyoung Chun, Dean M. Kleissas, R. Jacob Vogelstein, Eric Perlman, Randal Burns, Richard Huganir, Michael I. Miller
Journal: Neuron (2016)
Peripheral Blood Stem Cell Mobilization by G-CSF Alone and Engraftment Kinetics Following Autologous Transplantation in Children and Adolescents with Solid Tumor.
Authors: Hiroyoshi Watanabe, Tsutomu Watanabe, Hiroko Suzuya, Yoshifumi Wakata, Toshihiro Onishi, Ryuji Nakagawa, Yasuhiro Okamoto, Takanori Abe, Yoshifumi Kawano, Shoji Kagami, Yoichi Takaue
Journal: Blood (2005)
Single Oral Administration of KRN383, a Novel Flt3 Inhibitor, Induces Eradication of the Xenograft Tumor Harboring Flt3 Mutation in Mice.
Authors: Uichi Nishiyama, Masako Ozai, Rieko Yoshioka, Tetsuya Yoshino, Yuko Ogasawara, Miyuki Kitahori, Eiji Yoshioka, Kazuo Kubo, Yukiko Komeno, Mineo Kurokawa, Seishi Ogawa, Shigeru Chiba, Tatsushi Osawa, Tomoaki Kuwaki, Hisamaru Hirai, Atsushi Miwa
Journal: Blood (2004)
Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer
Authors: Ameet A. Chimote, Peter Hajdu, Alexandros M. Sfyris, Brittany N. Gleich, Trisha Wise-Draper, Keith A. Casper, Laura Conforti
Journal: Cancer Research (2016)

Tumor-infiltrating lymphocytes (TIL) are potent mediators of an antitumor response. However, their function is attenuated in solid tumors. CD8+ T-cell effector functions, such as cytokine and granzyme production, depend on cytoplasmic Ca2+, which is controlled by ion channels. In particular, Kv1.3 channels regulate the membrane potential and Ca2+ influx in human effector memory T (TEM) cells. In this study, we assessed the contribution of reduced Kv1.3 and Ca2+ flux on TIL effector function in head and neck cancer (HNC). We obtained tumor samples and matched peripheral blood from 14 patients with HNC. CD3+ TILs were composed of 57% CD4+ (82% TEM and 20% Tregs) and 36% CD8+ cells. Electrophysiology revealed a 70% reduction in functional Kv1.3 channels in TILs as compared with peripheral blood T cells from paired patients, which was accompanied by a decrease in Ca2+ influx. Immunofluorescence analysis showed that CD8+ TILs expressing high Kv1.3 preferentially localized in the stroma. Importantly, high expression of Kv1.3 correlated with high Ki-67 and granzyme B expression. Overall, these data indicate that defective Kv1.3 channels and Ca2+ fluxes in TILs may contribute to reduced immune surveillance in HNC. Cancer Res; 77(1); 53-61. ©2016 AACR.
Quality of Life in Survivors of Childhood and Adolescent Acute Myelogenous Leukemia (AML) Does Not Differ by Treatment (Bone Marrow Transplant (BMT) vs. Chemotherapy). A Report from the Children’s Oncology Group (COG).
Authors: H. Stacy Nicholson, Tianni Zhou, Zhengjia Chen, Kellie Moran, Charles Sklar, Lonnie Zeltzer, Joseph Neglia
Journal: Blood (2005)
You and Your Aging Parents
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America
Authors: Luciano J Costa, Michael Lill, Rosa F. Yeh, Robert K Stuart, Stephen Lim, Edmund K. Waller, Tsiporah B. Shore, Michael Craig, Cesar O. Freytes, Thomas C. Shea, Tulio E. Rodriguez, Ian W. Flinn, Terrance Comeau, Michael A. Pulsipher, Isabelle Bence-Bruckler, Pierre Laneuville, Philip Bierman, Andy I. Chen, Louie H. Yu, Shiva Patil, Yiping Sun, Elizabeth Armstrong, Angela Smith, Agnes Elekes, Kazunobu Kato, William Vaughan
Journal: Blood (2012)
Knockdown of HCK Reduces Cell Death and Erythroid Differentiation in Human CD34+ Hematopoietic Progenitor Cells
Authors: Fernanda Marconi Roversi, Fernando Vieira Pericole, Adriana da Silva Santos Duarte, Karla Priscila Ferro, Flávia Adolfo Corrocher, Bruna Palodetto, Ana Leda Longhini, Maurizio Botta, Sara T. Olalla Saad
Journal: Blood (2015)
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
Authors: Matthew H. Kulke, Dieter Hörsch, Martyn E. Caplin, Lowell B. Anthony, Emily Bergsland, Kjell Öberg, Staffan Welin, Richard R.P. Warner, Catherine Lombard-Bohas, Pamela L. Kunz, Enrique Grande, Juan W. Valle, Douglas Fleming, Pablo Lapuerta, Phillip Banks, Shanna Jackson, Brian Zambrowicz, Arthur T. Sands, Marianne Pavel
Journal: Journal of Clinical Oncology (2017)

Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg. Results Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were –0.81 for telotristat ethyl 250 mg ( P &lt; .001) and ‒0.69 for telotristat ethyl 500 mg ( P &lt; .001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were –0.9, –1.7, and –2.1, respectively. Responses, predefined as a BM frequency reduction ≥ 30% from baseline for ≥ 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole acetic acid versus placebo at week 12 ( P &lt; .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid.
COMPARISON OF LABORATORY DATA AMONG THE SIX DIFFERENT PRP SEPARATION SYSTEMS USING 144 SAMPLES
Authors: SH Lhee, JW Kim, JB Jeon, DY Lee
Journal: British Journal of Sports Medicine (2016)

Many systems for preparation of platelet-rich plasma (PRP) are commercially available, but comparative study among these systems is rare and only small sample size studies have been conducted. The purpose of this study was to characterize the platelet, white blood cell (WBC), red blood cell (RBC) concentrations, and CD 34 counts in the PRP produced by six commercially available PRP separation systems, using a single donor model. Twenty-four healthy humans who were not taking medication consented to donate 180 mL of blood. Whole blood samples were collected with appropriate ratio of anticoagulant, and each sample was simultaneously processed by PRP separation systems according to the manufacturer's protocol. Total of 144 samples were collected and analysed. After we obtained quantification of Platelet, WBC, RBC and CD34+ cell enumeration, the difference in mean platelet, WBC, RBC concentration and CD 34 counts among PRP separation systems was analysed. The GPS III (6.5±0.9) produced PRP with highest mean platelet concentration, whereas the Conditioned Plasma (2.0±0.7) and Tubex (2.2±1.0) produced PRP with lowest mean platelet concentration. The GPS III (4.7±0.8) produced PRP with highest mean WBC concentration, whereas the Conditioned Plasma (0.2±0.3) produced PRP with lowest mean WBC concentration. The Conditioned Plasma produced PRP with lowest mean RBC concentration (0.1±0.1). Regarding the collection efficiency of platelet, the Addcell (71.1±28.4) and GPS III (72.2±9.6) produced the highest PRP concentration, whereas the Tubex (26.2±12.0) produced with the lowest PRP concentration. Mean CD 34+ cell count did not differ among six different PRP separation systems. As lots of clinical researches using PRP used different separation systems, with little or no characterization of components of the PRP, this study will provide fundamental data to interpret lots of clinical researches conducted so far. This study will provide an accurate context for physician to interpret the results and thereby make informed decisions about how to use the various PRP separation systems to provide effective PRP treatment in clinical situations.
P0066 : Diastolic dysfunction is prognostic for mortality in liver transplanted patients with normal ejection fraction
Authors: T. Peeraphatdit, N. Naksuk, C. Thongprayoon, P. Phatharacharukul, C. Krittanawong, P. Ricci, R. Chaiteerakij, K. Klarich, L.R. Roberts
Journal: Journal of Hepatology (2015)
Joint effect of airflow limitation and emphysema on postoperative outcomes in early-stage nonsmall cell lung cancer
Authors: Sumin Shin, Hye Yun Park, Hyunkyung Kim, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Sang-Won Um, Myung Jin Chung, Hojoong Kim, O Jung Kwon, Jae Ill Zo, Eliseo Guallar, Juhee Cho, Young Mog Shim
Journal: European Respiratory Journal (2016)

This study aims to evaluate the joint effect of severity of airflow limitation and emphysema on postoperative pulmonary complications (PPCs) and overall survival after complete resection in patients with early-stage nonsmall cell lung cancer (NSCLC). We retrospectively studied 413 male patients with pathologic stage I or II NSCLC between 2007 and 2009. Severity of airflow limitation was defined based on forced expiratory volume in 1 s. Emphysema was defined by ≥5% low attenuation area at −950 HU. In multivariable-adjusted analyses, the adjusted odds ratio (aOR) for any PPC, comparing patients with moderate-to-severe airflow limitation to those without airflow limitation, was 2.23, and the aOR comparing patients with emphysema to those without emphysema was 1.77. However, the joint effect of airflow limitation and emphysema was much higher than expected from the independent effects of both factors (aOR 8.90). Moreover, patients with coexisting moderate-to-severe airflow limitation and emphysema had significantly poorer overall survival than any other group. Patients with moderate-to-severe airflow limitation and emphysema had almost nine times the risk of PPCs and poorer survival than patients with neither of these conditions. Integrated assessment of airflow limitation severity and emphysema is necessary for the optimal selection of candidates for lung resection surgery of early-stage NSCLC.
Inflammatory TH1 Cytokines in Target Tissues Promote the Recruitment of Alloreactive T Cells in Graft-Versus-Host Disease.
Authors: Jeanette Baker, Andreas Beilhack, Lu-en Wai, Stephan Schulz, Carolin Kiesel, Ryosei Nishimura, Enosh M Baker, Gilad Landan, Edward I Herman, Janelle Olson, Georg F Beilhack, Robert Negrin
Journal: Blood (2009)
Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells
Authors: Tobias Meissner, Anja Seckinger, Kari Hemminki, Uta Bertsch, Asta Foersti, Mathias Haenel, Jan Duering, Hans-Juergen Salwender, Hartmut Goldschmidt, Gareth J Morgan, Dirk Hose, Niels Weinhold
Journal: Blood (2015)
Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma
Authors: Hidenobu Ishii, Koichi Azuma, Kazuko Sakai, Takaaki Tokito, Kazuhiko Yamada, Kazuto Nishio, Tomoaki Hoshibo
Journal: Annals of Oncology (2015)